Sage Journals: Discover world-class research

Abstract

We present a case of an adolescent male with relapsed Hodgkin lymphoma involving the mediastinum two years following chemotherapy without radiotherapy. The patient was treated with second-line chemotherapy followed by high-dose chemotherapy and autologous stem cell transplant and then presented for evaluation of consolidative involved-field proton therapy (PT). Comparative treatment plans were developed with three-dimensional X-ray radiotherapy (3DXRT) and PT. PT substantially reduced the dose to the lungs, heart, esophagus, and total body compared with 3DXRT, resulting in treatment with PT. PT should reduce the risk of late side effects compared with 3DXRT, including secondary malignancies and cardiovascular disease.

Get full access to this article

View all access options for this article.

References

Goodman

, Riedel

, Serrano

et al. Long-term effects of high-dose chemotherapy and radiation for relapsed and refractory Hodgkin's lymphoma. J Clin Oncol., 2008; 26:5240–5247.

Kahn

, Flowers

, Xu

et al.

Does the addition of involved field radiotherapy to high-dose chemotherapy and stem cell transplantation improve outcomes for patients with relapsed/refractory Hodgkin lymphoma?

Int J Radiat Oncol Biol Phys., 2011; 81:175–180.

Wendland

, Asch

, Pulsipher

et al. The impact of involved field radiation therapy for patients receiving high-dose chemotherapy followed by hematopoietic progenitor cell transplant for the treatment of relapsed or refractory Hodgkin disease. Am J Clin Oncol., 2006; 29:189–195.

Poen

, Hoppe

, Horning

. High-dose therapy and autologous bone marrow transplantation for relapsed/refractory Hodgkin's disease: the impact of involved field radiotherapy on patterns of failure and survival. Int J Radiat Oncol Biol Phys., 1996; 36:3–12.

Hoppe

, Flampouri

, Su

et al. Consolidative involved-node proton therapy for stage Ia–IIIb mediastinal Hodgkin lymphoma: preliminary dosimetric outcomes from a phase II study. Int J Radiat Oncol Biol Phys, 2011in press.

Hoppe

. Hodgkin's disease: complications of therapy and excess mortality. Ann Oncol., 1997; 8:S115–S118.

Travis

, Gospodarowicz

, Curtis

et al. Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease. J Natl Cancer Inst., 2002; 94:182–192.

Mertens

, Liu

, Neglia

et al. Cause-specific late mortality among 5-year survivors of childhood cancer: the Childhood Cancer Survivor Study. J Natl Cancer Inst., 2008; 100:1368–1379.

Mulrooney

, Yeazel

, Kawashima

et al. Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort. BMJ., 2009; 339:b4606.

10.

Tukenova

, Guibout

, Oberlin

et al. Role of cancer treatment in long-term overall and cardiovascular mortality after childhood cancer. J Clin Oncol., 2010; 28:1308–1315.

11.

Eich

, Haverkamp

, Engert

et al. Biophysical analysis of the acute toxicity of radiotherapy in Hodgkin's lymphoma—a comparison between extended field and involved field radiotherapy based on the data of the German Hodgkin Study Group. Int J Radiat Oncol Biol Phys., 2005; 63:860–865.

12.

Papadakis

, Tan

, Heller

et al. Growth and final height after treatment for childhood Hodgkin disease. J Pediatr Hematol Oncol., 1996; 18:272–276.

Consolidative Proton Therapy Following High-dose Chemotherapy and Autologous Stem Cell Transplant in an Adolescent with Relapsed Hodgkin Lymphoma

Abstract

Get full access to this article

References